Profund Advisors LLC decreased its holdings in shares of HCA Healthcare Inc (NYSE:HCA) by 20.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,880 shares of the company’s stock after selling 2,053 shares during the quarter. Profund Advisors LLC’s holdings in HCA Healthcare were worth $1,065,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also modified their holdings of HCA. Westside Investment Management Inc. purchased a new position in shares of HCA Healthcare during the second quarter valued at $34,000. NEXT Financial Group Inc purchased a new position in HCA Healthcare in the second quarter valued at about $43,000. Rational Advisors LLC lifted its position in shares of HCA Healthcare by 5,118.2% in the first quarter. Rational Advisors LLC now owns 574 shares of the company’s stock worth $75,000 after buying an additional 563 shares during the last quarter. Cornerstone Advisors Inc. lifted its position in shares of HCA Healthcare by 19.6% in the first quarter. Cornerstone Advisors Inc. now owns 587 shares of the company’s stock worth $77,000 after buying an additional 96 shares during the last quarter. Finally, Alpha Windward LLC lifted its position in shares of HCA Healthcare by 50.9% in the second quarter. Alpha Windward LLC now owns 608 shares of the company’s stock worth $89,000 after buying an additional 205 shares during the last quarter. Institutional investors and hedge funds own 70.19% of the company’s stock.
In related news, SVP Robert A. Waterman sold 33,786 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $134.98, for a total transaction of $4,560,434.28. Following the completion of the transaction, the senior vice president now owns 279,551 shares of the company’s stock, valued at approximately $37,733,793.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Patricia F. Elcan acquired 250 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were acquired at an average cost of $124.10 per share, with a total value of $31,025.00. The disclosure for this purchase can be found here. 2.70% of the stock is currently owned by insiders.
Shares of NYSE HCA traded down $0.59 during trading hours on Monday, hitting $128.48. 514,533 shares of the company’s stock were exchanged, compared to its average volume of 1,351,520. HCA Healthcare Inc has a 1-year low of $110.31 and a 1-year high of $147.42. The stock has a market capitalization of $43.88 billion, a price-to-earnings ratio of 13.15, a PEG ratio of 1.10 and a beta of 0.87. The company’s 50-day moving average price is $126.64 and its 200-day moving average price is $129.13.
HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $2.21 earnings per share for the quarter, missing the consensus estimate of $2.49 by ($0.28). HCA Healthcare had a negative return on equity of 135.90% and a net margin of 7.46%. The business had revenue of $12.60 billion for the quarter, compared to analyst estimates of $12.61 billion. During the same period in the prior year, the firm posted $2.29 EPS. HCA Healthcare’s revenue for the quarter was up 9.3% on a year-over-year basis. On average, research analysts predict that HCA Healthcare Inc will post 10.4 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Tuesday, September 3rd will be given a dividend of $0.40 per share. The ex-dividend date is Friday, August 30th. This represents a $1.60 annualized dividend and a dividend yield of 1.25%. HCA Healthcare’s dividend payout ratio is presently 16.38%.
A number of analysts have weighed in on HCA shares. UBS Group boosted their price target on HCA Healthcare from $172.00 to $181.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Stephens set a $150.00 price target on HCA Healthcare and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Bank of America raised HCA Healthcare from an “underperform” rating to a “neutral” rating and boosted their price target for the stock from $130.00 to $137.00 in a research report on Friday, September 6th. Mizuho set a $153.00 price target on HCA Healthcare and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Finally, Goldman Sachs Group raised HCA Healthcare from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $147.00 to $160.00 in a research report on Wednesday, July 10th. Three analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $155.29.
HCA Healthcare Profile
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
Featured Story: Trade War
Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare Inc (NYSE:HCA).
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.